Type 2 diabetes<unk>  is used in combination with proper diet and exercise to help people with type2 diabetes lower their blood sugar levels. It can be used alongside other medications for type2 diabetes such as metformin, sulfonylureas, and insulin. Weight and blood pressure<unk>  causes moderate reductions in blood pressure and body weight. These effects are likely due to the excretion of glucose in the urine and a slight increase in urinary sodium excretion. In clinical trials, patients taking<unk>  lost an average of 2% of their baseline body weight. A higher percentage of people taking<unk>  achieved weight loss greater than 5% from their baseline. The medication reduced systolic blood pressure by 3 to 5millimeters of mercury (mmHg). The effects on blood pressure and body weight are generally viewed as favorable, as many patients with type2 diabetes have high blood pressure or are overweight or obese. Heart & kidney disease<unk>  appears to reduce the likelihood of hospitalization for heart failure or progression of chronic kidney disease in people with type2 diabetes.<unk>  may reduce the likelihood of death due to cardiovascular causes in people with type2 diabetes who have known cardiovascular disease. One concern regarding the trial on which these claims are based is that the different arms received different amounts of other medications; thus, the reduced risk cannot necessarily be attributed to<unk> . In some countries it has also been approved to reduce the risk of death from cardiovascular causes in people with type2 diabetes and heart disease. Treatment guidelines Guidelines by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend SGLT-2 inhibitors like<unk>  as second-line medications after metformin for type2 diabetes in people with heart failure or chronic kidney disease. For type2 diabetes with established cardiovascular disease, the guidelines recommend either a SGLT-2 inhibitor or a GLP-1 agonist as second-line medications after metformin. In all other type2 diabetes cases, SGLT-2 inhibitors like<unk>  can be appropriate second-line options if blood glucose control or weight loss are treatment priorities. They are less appropriate if cost is a major factor. In the United Kingdom,<unk>  is typically only recommended together with metformin if a sulfonylurea cannot be taken. Type 1 diabetes<unk>  is not recommended for type 1 diabetes. One trial studied its use in addition to insulin in people with type 1 diabetes. The medications delivered modest improvements in blood glucose control and body weight but were associated with an increased risk of diabetic ketoacidosis, a dangerous complication of diabetes.<unk>  is not approved by the U.S. Food and Drug Administration (FDA) for use in type 1 diabetes.
Empagliflozin
Canagliflozin
Linagliptin
Dapagliflozin
Sotagliflozin
Liraglutide
Vildagliptin
Pioglitazone